Plasma levels of the active form of suPAR are associated with COVID-19 severity.
作者信息
Huang Mingxiang, Li Linlin, Shen Jianshan, Wang Yao, Wang Rui, Yuan Cai, Huang Mingdong, Jiang Longguang
机构信息
Department of Clinical Laboratory, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, 350008, Fujian, China.
College of Chemistry, Fuzhou University, Fuzhou, 350116, Fujian, China.
出版信息
Crit Care. 2020 Dec 29;24(1):704. doi: 10.1186/s13054-020-03336-0.
Abstract
摘要
相似文献
1
Plasma levels of the active form of suPAR are associated with COVID-19 severity.
Crit Care. 2020 Dec 29;24(1):704. doi: 10.1186/s13054-020-03336-0.
2
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.
Cell Rep Med. 2022 Feb 25;3(3):100560. doi: 10.1016/j.xcrm.2022.100560. eCollection 2022 Mar 15.
3
Elevated soluble urokinase plasminogen activator receptor is associated with renal dysfunction in a Chlorocebus atheiops COVID-19 model.
J Med Primatol. 2023 Apr;52(2):131-134. doi: 10.1111/jmp.12626. Epub 2022 Nov 15.
4
Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.
J Crit Care. 2015 Jun;30(3):476-80. doi: 10.1016/j.jcrc.2015.01.006. Epub 2015 Jan 9.
5
Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in psoriasis patients and correlation with disease severity.
Acta Dermatovenerol Alp Pannonica Adriat. 2015;24(4):73-5. doi: 10.15570/actaapa.2015.19.
6
Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Eur J Haematol. 2002 Jul;69(1):43-9. doi: 10.1034/j.1600-0609.2002.01732.x.
7
Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Clin Chim Acta. 2013 Jan 16;415:138-44. doi: 10.1016/j.cca.2012.10.038. Epub 2012 Oct 29.
8
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Anticancer Res. 2004 May-Jun;24(3b):1981-5.
9
Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia.
Int J Environ Res Public Health. 2019 Mar 21;16(6):1035. doi: 10.3390/ijerph16061035.
10
Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Transl Res. 2013 Nov;162(5):287-96. doi: 10.1016/j.trsl.2013.07.003. Epub 2013 Aug 1.
引用本文的文献
1
Soluble Urokinase Plasminogen Activator Receptor: A Useful Marker for Predicting Mortality in COVID-19 Patients.
Cureus. 2024 Nov 25;16(11):e74438. doi: 10.7759/cureus.74438. eCollection 2024 Nov.
2
Evaluation of Soluble Urokinase Plasminogen Activator Receptor in COVID-19 Patients.
J Clin Med. 2024 Oct 23;13(21):6340. doi: 10.3390/jcm13216340.
3
Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument.
Biomark Insights. 2023 Nov 29;18:11772719231210407. doi: 10.1177/11772719231210407. eCollection 2023.
4
Novel inflammatory biomarkers in the prognosis of COVID-19.
Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231199679. doi: 10.1177/17534666231199679.
5
Endotheliopathy in Acute COVID-19 and Long COVID.
Int J Mol Sci. 2023 May 4;24(9):8237. doi: 10.3390/ijms24098237.
6
Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Int J Mol Sci. 2023 Apr 13;24(8):7177. doi: 10.3390/ijms24087177.
7
Urokinase System in Pathogenesis of Pulmonary Fibrosis: A Hidden Threat of COVID-19.
Int J Mol Sci. 2023 Jan 10;24(2):1382. doi: 10.3390/ijms24021382.
8
The Association of Genotype and Soluble suPAR Serum Level with COVID-19-Related Lung Damage Severity.
Int J Mol Sci. 2022 Dec 19;23(24):16210. doi: 10.3390/ijms232416210.
9
From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?
Biomedicines. 2022 Oct 18;10(10):2620. doi: 10.3390/biomedicines10102620.
10
suPAR: An Inflammatory Mediator for Kidneys.
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
本文引用的文献
1
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22.
2
COVID-19 and pneumonia: a role for the uPA/uPAR system.
Drug Discov Today. 2020 Aug;25(8):1528-1534. doi: 10.1016/j.drudis.2020.06.013. Epub 2020 Jun 18.
3
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.
Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.
4
An ELISA method detecting the active form of suPAR.
Talanta. 2016 Nov 1;160:205-210. doi: 10.1016/j.talanta.2016.07.004. Epub 2016 Jul 4.
5
Structure of human urokinase plasminogen activator in complex with its receptor.
Science. 2006 Feb 3;311(5761):656-9. doi: 10.1126/science.1121143.
6
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.
J Acquir Immune Defic Syndr. 2005 May 1;39(1):23-31. doi: 10.1097/01.qai.0000157950.02076.a6.
7
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64. doi: 10.1073/pnas.022652999. Epub 2002 Jan 29.
Zotero 插件